生物安全法案出现积极变化，重视CXO机会！

Investment Rating - The industry rating is "Outperform the Market" [7] Core Insights - The report emphasizes the positive changes in the Biodefense Act and highlights the investment opportunities in external demand-oriented CXO companies due to the expected improvement in overseas financing and the easing of policy uncertainties [4][26] - The report notes that the recent Federal Reserve interest rate cut is expected to enhance overseas investment in the biotech sector, which will benefit CDMO companies through increased overseas orders [4][21] - The new Biodefense Act is less stringent than previous versions, which is expected to have a limited impact on external demand-oriented CXO companies, potentially lifting valuation pressures on the sector [4][26] Summary by Sections Market Review - During the week of December 8-12, 2025, the CITIC Pharmaceutical Index fell by 1.1%, underperforming the CSI 300 Index by 1.0 percentage points, ranking 15th among CITIC's primary industry classifications [3][32] - Year-to-date, the CITIC Pharmaceutical and Biotech Index has risen by 15.6%, underperforming the CSI 300 Index by 0.8 percentage points, ranking 16th among CITIC's industry classifications [3][32] - The top five performing stocks for the week were: Zhaoyan New Drug (+23.4%), Rejing Biotech (+16.8%), Haichuang Pharmaceutical (+13.9%), Wanze Co. (+13.4%), and Zhongyao Holdings (+13%) [3][49] Investment Opportunities - The report suggests focusing on innovative drugs, particularly those with revenue and commercialization capabilities, as well as potential big BD targets based on technological and industrial trends [5] - It also highlights opportunities in medical devices, especially in areas like endoscopy and robotics, and emphasizes the importance of innovative consumables supported by national policies [5] - The report indicates a shift towards domestic demand-driven companies as the central economic work conference emphasizes building a strong domestic market [5] Recommendations - The report recommends a focus on the following companies: Kangfang Biotech, WuXi AppTec, Kanglong Huacheng, Baiaosaitu, Bairen Medical, and Kangzhong Medical for December [5][12]